Author: Ravi Shankar

HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — BioForce Nanosciences Holdings, Inc. (OTC: BFNH) (“BFNH”) (“Company”) announces the expansion of its oil and gas asset portfolio beyond Nevada through a 100% leasehold interest in two oil and gas leases totaling approximately 67.59 acres in Liberty County, Texas.

The Texas properties include:

• An approximately 40.19-acre lease assigned to BFNH by CELT eResources LLC; and
• An approximately 27.40-acre lease entered into by BFNH with a private lessor.

The Texas General Land Office approved the 40.19-acre lease assignment. The assignment was recorded in the official public records of Liberty County, Texas, under Document No. 2026029454 on October 6, 2026. The separate 27.40-acre private lease is dated October 4, 2026.

BFNH’s 100% leasehold interest remains subject to the terms and conditions of the applicable leases, including lessor royalty interests, overriding royalties, production burdens, and other applicable obligations.

Herrin-1 Opportunity

BFNH has received an engineering evaluation prepared by Hagen Consulting, LLC, effective January 1, 2026, for the Herrin-1 property. For the property and ownership evaluated in that report, the evaluation identifies gross estimate “Proved Developed Behind Pipe Reserves” of:

Reserve Category	Estimate Gross Reserves
Oil	285,730 barrels
Natural Gas	23,512,340 Mcf *

*The reported natural-gas volume is an estimated 23.5 billion cubic feet.

Herrin-1 is currently shut in and not producing. BFNH is conducting a comprehensive feasibility analysis of the gross estimates, including, but not limited to, engineering, operations, infrastructure, title, regulatory, environmental, production, and financial considerations.

Based on currently available information, BFNH estimates that the capital required to evaluate, repair, rework, equip, and potentially return Herrin-1 to production could be at least approximately $2.5 million or more. This preliminary estimate is subject to change and does not constitute a final development budget, financing commitment, or decision to undertake any particular work.

The evaluation was prepared for CELT eResources LLC before the lease transfer to BFNH and has not been independently updated or reissued for BFNH.

BFNH has not made a final determination regarding the timing, scope, funding, execution, or commercial viability of any potential work on Herrin-1.

Portfolio Expansion and Additional Opportunities

In addition to evaluating Herrin-1, BFNH continues to assess potential opportunities to expand and diversify its energy portfolio, including opportunities outside Liberty County, Texas.

Potential opportunities may include additional oil and gas leasehold interests, prospective resource projects, strategic acquisitions, technical partnerships, and other assets that could complement the Company’s existing activities. BFNH’s objective is to identify opportunities that may support the development of multiple initiatives over time while maintaining disciplined review of title, ownership, reserves, engineering, infrastructure, regulatory, environmental, financing, and commercial considerations.

No assurance can be given that BFNH will acquire or develop any additional assets, that any potential opportunity will result in production or revenue, or that any such opportunity will contribute to the Company’s growth. Any future acquisition, development, partnership, or investment decision will be subject to further due diligence, applicable approvals, available financing, and definitive agreements.

Management Statement

“BFNH has established direct control of two Liberty County leasehold interests totaling approximately 67.59 acres and is advancing a disciplined technical evaluation of the Herrin-1 opportunity,” said Gustavo Taboada, BFNH’s Chief Geoscience Officer.

He further stated, “Our immediate priority is to evaluate the available geological, engineering, wellbore, infrastructure, title, regulatory, environmental, and financial information before determining whether any repair, rework, re-equipping, or production-restoration program is justified or economically viable. We are also reviewing additional opportunities that could broaden BFNH’s energy portfolio and support the advancement of multiple initiatives over time, subject to appropriate due diligence and available financing.”

“Expanding beyond Nevada into Texas gives BFNH an additional opportunity and broadens our asset portfolio,” said Richard Kaiser, Interim Chief Executive Officer, Chief Financial Officer, and Director of BFNH. “We are taking a disciplined approach by completing the necessary technical and financial analysis before determining whether and how to advance Herrin-1 as well as the Company’s other holdings.”

Related-Party Disclosure

The approximately 40.19-acre lease was assigned to BFNH by CELT eResources LLC, an entity under common control with BFNH through Nexus Capital Investments, Inc. The assignment is therefore a related-party transaction. Nexus Capital Investments, Inc. is BFNH’s majority shareholder.

About BioForce Nanosciences Holdings, Inc.

BioForce Nanosciences Holdings, Inc. (OTC: BFNH) is a publicly traded company pursuing and evaluating oil/gas opportunities across its asset portfolio, including its Nevada leases and its newly expanded Texas leasehold interests. The Company evaluates opportunities based on technical, operational, regulatory, and financial considerations – www.bioforceeclipse.com.

Cautionary Statement Regarding Gross Reserve Information

The reserve estimate information in this release comes from the Hagen Consulting, LLC engineering evaluation prepared for CELT eResources LLC, effective January 1, 2026. BFNH received it in connection with the completed lease acquisition. The estimates remain subject to the assumptions, limitations, ownership interests, methodology, definitions, and effective date stated in that evaluation. The reported volumes apply only to the Herrin-1 property and ownership evaluated in the report and do not apply to the separate approximately 27.40-acre lease. Both CELT eResources, LLC, a Texas limited liability company, and BFNH are controlled by Nexus Capital Investments, Inc. (“Nexus”).

The estimated reported volumes do not guarantee production, recovery, revenue, profitability, or shareholder returns. Herrin-1 is not currently producing, and BFNH has not made a final decision regarding development, funding, reactivation, production, timing, scope, or commercial viability.

Reserve estimates do not guarantee production, recovery, revenue, profitability, or shareholder returns. Actual results may differ materially due to reservoir performance, geological conditions, wellbore and equipment condition, completion requirements, title and ownership matters, permitting, regulatory and environmental requirements, operating costs, commodity prices, financing availability, infrastructure requirements, and other factors.

The fact that Herrin-1 has been evaluated as containing estimated reported reserve volumes does not mean that the well is currently producing or that BFNH has determined that production can be restored economically.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of applicable securities laws. These statements include, among others, statements regarding BFNH’s feasibility analysis, potential engineering and technical work, Herrin-1, potential repair, rework, reactivation, equipping, or production activities, estimated capital requirements, funding, portfolio expansion, potential acquisitions, strategic partnerships, development opportunities, commercial viability, and future disclosures. Forward-looking statements are generally identified by words such as “may,” “could,” “would,” “will,” “expects,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continues,” “seeks,” “evaluates,” “anticipates,” and similar expressions, although not all forward-looking statements contain these words.
The preliminary capital estimate described in this release is subject to change and is not a financing commitment, development budget, or commitment to proceed with any proposed work. Any future activity remains subject to additional technical, engineering, operational, title, regulatory, environmental, infrastructure, financial, and commercial analysis. BFNH makes no assurance regarding the timing, scope, funding, execution, production, recovery, revenue, profitability, commercial viability, or ultimate outcome of any potential work associated with Herrin-1 or any other opportunity under evaluation. BFNH also makes no assurance that it will acquire, develop, finance, or complete any additional project or transaction. Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional factors that could cause actual results to differ materially are discussed in BFNH’s filings with the U.S. Securities and Exchange Commission. BFNH undertakes no obligation to update forward-looking statements except as required by applicable law.

For Further Information, Contact:

BioForce Nanosciences Holdings, Inc.
Phone: (757) 306-6090
Email: info@bioforceeclipse.com
Website: https://bioforceeclipse.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f6da9721-af30-4819-a8a8-74d8306089fb

MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 120 patents and pending applications globally and over 60 lighting and home décor websites, with a mission to make homes and buildings safe and smart as the new standard, today provides a corporate update.

Highlights Recent Events

• The combined SKYX and Deako pipeline is estimated at over 4 million units with an expected average selling price of approximately $50 per product.
• SKYX’s subsidiary Deako announced it will supply over 80,000 units to 1,000 homes of prominent builder Maronda Homes.
• The Company recently signed an agreement to supply two 65 stories luxury Trump Towers with over 2.2 million SQF in one of India’s leading tech cities Hyderabad, expecting to deploy tens of thousands of units.
• SKYX recently announced it will supply its technologies during a renovation of a Marriott city center hotel in Durham, NC.

Maintaining Strong Cash Position

• The Company reported $27.7 million in total cash, cash equivalents, and restricted cash as of the end of the second quarter of 2026 and continues to maintain a strong cash position to achieve its business goals, including achieving positive cash flow as it exits 2026.
• The Company reported 10 consecutive quarters of year-over-year growth and expects to continue this pattern of quarterly growth.

SKYX Patented Turbo Heater Fan

• Despite a very hot summer, SKYX’s sales of its patented Turbo Heater Fan continued to grow during the summer with all retailers, including Home Depot, Lowe’s, Target, Walmart, Costco, Amazon, Wayfair, and through SKYX’s e-commerce platform of 60 websites.
• The Company expects sales of its Turbo Heater Fan to grow significantly during the fall and winter seasons in both the retail and builder segments.
• Due to increasing demand, SKYX intends to launch new designs in both larger and smaller sizes and in five different colors.

SKYX Deako Merger Highlights

Synergies

• SKYX’s full product line is expected to create an opportunity to increase Deako’s revenue per home by up to fivefold.
• Synergies between SKYX and Deako are expected to reduce annual cash expenses by over $6 million. In addition to expected revenues from sales, both SKYX and Deako use the razor-and-blades model and are expected to provide additional future revenues from upgrades, as well as recurring revenue opportunities from plug & play product interchangeability, AI services, monitoring, subscriptions, and licensing, among other sources.
• The merger opens the door for Deako’s products in SKYX projects, including Marriott and European hotels and Miami’s $4 billion Smart City.

Stock Consideration & Lock-Up

• In consideration for the merger, SKYX issued 25,000,000 shares of common stock, subject to a 12-month full lock-up (followed by quarterly leak-out releases at 12, 15, 18, and 21 months after the closing, with share sales subject to a Rule 10b5-1 trading plan).

Deako’s Market Acceptance and Strategic Relations

• Deako’s lead investors include Paul Jacobs, former Chairman and CEO of Qualcomm; Deako’s former board member Marwan Fawaz served as CEO of Nest (Google).
• Deako has recently extended its supply agreement with leading builders D.R. Horton and Stone Martin.
• Deako has shipped over 32 million units, including its smart plug-in wall switches, and generated over $26 million in revenue in 2025.
• Deako is a leading technology supplier with over $26M in 2025 revenues and has shipped over 32 million units, including its smart home plug-in wall switches, to over 50 U.S. homebuilder customers, including D.R. Horton, Toll Brothers, Risewell Homes, Adams Homes, Maronda Homes, Shea Homes, and Schumacher Homes, among many others.
• The merger between SKYX and Deako will enable SKYX to offer an A-to-Z AI and smart home plug & play solution for homes and buildings, including wall outlets, wall switches, and ceiling outlet boxes for smart home and safety products, lighting, ceiling fans, and smoke detectors, among others.
• Most smart home solutions today require time-consuming and costly wired installation and address only part of the A-to-Z opportunity, while the combined company aims to offer a complete A-to-Z AI and plug & play smart home solution.

SKYX’s Signed Agreements Prior to Merger with Builder / Hotel Segments

• The Company recently signed an agreement to supply two 65 stories luxury Trump Towers with over 2.2 million SQF in one of India’s leading tech cities Hyderabad, expecting to deploy tens of thousands of units.
• SKYX recently announced it will supply its technologies during a renovation of a Marriott city center hotel in Durham, NC.
• SKYX announced its technology will become a brand standard for European hotel developer Group OTT, a developer of over 250 hotels and buildings across Europe.
• SKYX’s future U.S. and international projects include Miami’s new $4 billion Smart City and projects in North Carolina, Austin, San Antonio, South Florida, New York, Europe, Saudi Arabia, and Egypt.
• SKYX is progressing toward its goal to become a brand standard for national and international hotel chains and builders.

Technology Licensing and Roadmap

• SKYX has recently signed a licensing agreement for its advanced technologies with Eurofase, a leading lighting company in the U.S., Canada, and global markets.
• SKYX expects to continue its licensing model for its vast patent portfolio as part of its safety code standardization efforts, as well as through licensing to leading tech companies.
• SKYX will be launching a new AI-driven system and infrastructure for its e-commerce platform of 60 websites, expected to significantly increase its conversion rate and sales.
• The Company secured U.S. and global strategic manufacturing partnerships with premier manufacturers in the U.S., Vietnam, Taiwan, China, and Cambodia.

Safety Standardization Mandatory Code and Insurance Exposure

• SKYX’s Safety Code Standardization Team is receiving support from a prominent new leader in connection with its government safety agency process for mandatory safety standardization of its electrical ceiling outlet/receptacle technology.
• SKYX’s code team is led by industry veterans Mark Earley, former head of the National Electrical Code (NEC), and Eric Jacobson, former President and CEO of the American Lighting Association (ALA). The Company’s Safety Code Standardization Team believes it will garner assistance from additional safety organizations in its mandatory safety code standardization efforts based on the product’s significant safety aspects. Mr. Earley and Mr. Jacobson were instrumental in numerous code and safety changes in both the electrical and lighting industries. Both strongly believe that, considering the Company’s standardization progress, including ANSI / NEMA (American National Standards Institute / National Electrical Manufacturers Association) voting to approve its product specification and its technology being voted into 10 segments of the NEC Code Book, its technology has met the necessary safety conditions for becoming a ceiling safety standardization requirement for homes and buildings.
• The Company strongly believes its products can save insurance companies many billions of dollars annually by minimizing risks (e.g., reducing fires, ladder fall injuries, and electrocutions). Management expects that insurance companies will use the Company’s range and variations of its safe advanced plug & play products to reduce their exposure and minimize their risks. 

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced, safe, smart and AI platform technologies, with over 120 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home décor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target,” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become mandatory under the National Electrical Code (NEC), code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws. 

Investor Relations Contact:

Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com

Ronald A. Both
Encore Investor Relations
rb@encore-ir.com

Acquisition Structured With No Shareholder Dilution; Company Remains Debt-Free With Acquisition Funding Already in Place

Company to Rebrand as “GPU Exchange” and Plans to Change Its Nasdaq Ticker to “XGPU”

Due Diligence Substantially Complete; Closing Anticipated in Early November 2026

LAKEWOOD, NJ, Oct. 22, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“Reliance,” “EZRA” or the “Company”) today announced that on September 23, 2026, it executed a non-binding letter of intent (the “LOI”) to acquire the assets of a GPU cloud provider and marketplace operator delivering on-demand computing infrastructure for AI training, inference and other demanding workloads. The proposed acquisition would mark Reliance’s entry into the AI cloud market, with plans to scale rapidly through investment in a Company-owned GPU fleet and expansion of the acquisition target’s proprietary marketplace.

The business being acquired delivers on-demand computing capacity for artificial intelligence and other compute-intensive applications while enabling third-party GPU owners to earn revenue by offering their hardware through its platform. Reliance intends to build on this operating foundation by acquiring additional graphics processing units (“GPUs”), increasing available computing capacity and broadening marketplace participation.

The proposed acquisition is structured to result in no dilution to existing shareholders, as the purchase price is payable entirely in cash and no shares of the Company’s common stock will be issued as consideration for the acquisition, and the funds required to complete the transaction are already in place. Under the LOI, $3,375,000 is payable at closing, consisting of $3,000,000 in cash and $375,000 funded into escrow. A further $375,000 is payable 12 months after closing. Both $375,000 payments are subject to the achievement of specified milestones, and the Company will also pay $250,000 of consulting fees to the founder of the business over the 12 months following closing. The LOI also provides for an optional $500,000 investment by the Company in a related company of the seller. Reliance reiterated that it is debt-free, having retired 100% of its term debt. Due diligence is substantially complete, and the Company anticipates closing in early November 2026, subject to finalizing definitive agreements and satisfying applicable closing conditions.

In connection with this strategy, Reliance plans to adopt GPU Exchange as its doing-business-as (“DBA”) name and change its Nasdaq trading symbol from EZRA to XGPU. Following completion of the acquisition, the acquired business would operate under the GPU Exchange brand. The Company will announce the effective date of any ticker change separately. Its shares currently continue to trade under EZRA.

“The proposed acquisition provides an operating foundation for our entry into AI infrastructure, with a clear strategy to scale substantially,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “We believe this is the most significant step in the Company’s evolution to date. We are pursuing this acquisition with no outstanding debt, funding already in place and no dilution to existing shareholders.”

“Our focus is execution: acquiring and deploying GPUs, growing the customer base and making it easier for hardware owners to earn revenue through the marketplace,” said Judah Korman, Chief Operating Officer of Reliance Global Group. “By combining our own GPU fleet with third-party capacity, we intend to scale supply rapidly and serve more customers through a single platform. GPU Exchange will bring these efforts together under one brand.”

While Reliance continues to operate, enhance and grow the RELI Exchange platform, the Company believes the proposed acquisition creates new opportunities for expansion and scale.

Entering the Market with a Strategy for Rapid Scale

Following completion of the acquisition, Reliance intends to pursue growth through two complementary initiatives:

• Acquire and scale a Company-owned GPU fleet. Invest in GPUs to provide additional computing capacity for AI training, inference, rendering and other demanding workloads.
• Grow the proprietary GPU marketplace. Invest in the platform, attract additional customers and providers, and make it easier for individuals, businesses and infrastructure operators to offer GPU capacity and earn revenue when customers use it.

The Company-owned fleet would complement third-party capacity available through the marketplace, allowing the business to grow through both direct infrastructure investment and increased provider participation.

Reliance’s objective is to establish GPU Exchange as an accessible destination for customers seeking GPU computing power and hardware owners seeking to monetize available capacity. The Company intends to use the acquisition target’s existing platform as the foundation for accelerating customer adoption, increasing computing supply and scaling operations.

Transaction Status

The LOI is non-binding, and the acquisition has not yet closed. Due diligence is substantially complete, and completion remains subject to finalizing definitive agreements and satisfying applicable closing conditions. Reliance anticipates closing in early November 2026 and expects to provide additional updates as the transaction progresses.

About the Acquisition Target

The acquisition target is a GPU cloud provider and marketplace operator delivering on-demand computing resources for artificial intelligence, machine learning, rendering and other demanding workloads. Its proprietary GPU marketplace connects customers with available computing capacity and enables third-party hardware owners to earn rental revenue.

About Reliance Global Group, Inc.

Reliance Global Group, Inc. (Nasdaq: EZRA) operates insurance and technology businesses and pursues opportunities to build and scale AI-related platforms. Through the proposed acquisition, the Company intends to enter the GPU cloud and AI infrastructure market and rapidly scale the business under the planned GPU Exchange brand. Additional information is available at https://www.relianceglobalgroup.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may be identified by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “target,” “project,” “potential,” or similar expressions, or by discussions of strategy, plans or intentions. Forward-looking statements in this press release include, without limitation, statements regarding: the proposed acquisition, including its anticipated timing, funding and non-dilutive structure; the payment of the closing, escrow, milestone and consulting amounts; the optional investment in a related company of the seller; the negotiation and execution of definitive agreements; the Company’s planned entry into the GPU cloud and AI infrastructure market; the planned adoption of the GPU Exchange DBA and XGPU trading symbol; GPU fleet acquisitions and deployment; marketplace growth; the pace and scale of business development; and anticipated business benefits.

These statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may differ materially from those expressed or implied by these forward-looking statements.

Such risks and uncertainties include, without limitation: the non-binding nature of the LOI and the risk that definitive agreements are not executed, closing conditions or applicable approval requirements are not satisfied, or the acquisition is delayed or not completed; the risk that the Company’s continuing due diligence identifies matters that adversely affect the acquisition target or the terms of the acquisition; the risk of the loss of customers, GPU providers or key personnel in connection with the transfer of the business; the Company’s ability to integrate and rapidly scale the acquired business; the capital required to execute its growth plans, including the acquisition of a Company-owned GPU fleet, which will require capital beyond the cash required to complete the proposed acquisition and may be funded through equity financings that would be dilutive to existing shareholders; the Company’s ability to access additional capital on acceptable terms, or at all; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; the Company’s ability to implement the planned GPU Exchange DBA and XGPU trading symbol change; GPU availability, pricing and technological obsolescence; customer demand, utilization and competition; and general business, economic, market and geopolitical conditions. Additional information regarding these and other factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, copies of which are available free of charge at www.sec.gov.

There can be no assurance that the proposed acquisition, branding or ticker changes will be completed or that anticipated growth or benefits will be realized. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: EZRA@crescendo-ir.com

Turnover of 177 million euros in the third quarter
supported by a 29% increase in energy production

Capacity objectives reached one quarter ahead of schedule

  

Turnover of 177.4 million euros in the third quarter of 2026

• Energy Sales: strong increase of +26% compared with Q3 2025 at constant exchange rates, to 111.5 million euros, driven by the contribution of new capacity, improved resource levels and a significant reduction in curtailment (-41%)
• Renvolt: down -21% at constant exchange rates, to 53.9 million euros, in the third quarter due to the phasing of construction projects. Over nine months, Renvolt nevertheless records solid growth of +16%
• Voltalia Hub: up +22% at constant exchange rates, to 12.1 million euros, supported by growth across all specialised activities

Operational capacity and production indicators as of September 30, 2026

• Energy production up +11% to 4.1 terawatt-hours (including +29% in the third quarter), with curtailment in Brazil down -32% over the first nine months. This strong increase in production benefits from the contribution of new power plants, the sharp reduction in curtailment and improved solar and wind resources
• Capacity in operation and under construction up +8% to 3.6 gigawatts, including 3.0 gigawatts in operation (+18%)

2026 operational and financial objectives

• Capacity objective reached one quarter ahead of schedule: 3 gigawatts of capacity in operation reached as early as September, in addition to 563 megawatts under construction, bringing total capacity in operation and under construction to around 3.6 gigawatts
• 2026 EBITDA objective of between 210 and 230 million euros confirmed

Continued execution of the SPRING transformation plan

• Tighter cost control: continued structural savings and reduction in development costs, thanks to a simplified organisation and stricter project selection
• More selective capital allocation: investments and resources focused on the most mature and value-creating projects, notably through strategic partnerships, such as the one with IFC, enabling equity requirements to be shared and capital allocation to be optimised.
• Disposal programme¹: continued processes relating to non-strategic assets and activities, with value preservation and the gradual deleveraging of the Group as priorities
• Improved operational performance: production up +29% in the third quarter, driven by improved asset availability, lower operating costs and greater selectivity in the projects launched into construction, curtailment down -41%, and annual capacity in operation objective reached several months ahead of schedule.

Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energy, today publishes its turnover for the third quarter of 2026.

Robert Klein, Chief Executive Officer of Voltalia, states: “Our operational performance improves markedly this quarter, with production up 29% and our objective of 3 GW of capacity in operation reached one quarter ahead of schedule. As part of SPRING, we are continuing, with discipline, to improve our profitability, our cash flow generation and our capital allocation. We confirm our 2026 EBITDA objective.”

***

Nine-month (9M) and third-quarter (Q3) 2026 turnover

In million euros	9M 2026	9M 2025	Var. at current exchange rates	Var. at constant exchange rates	Q3 2026	Q3 2025	Var. at current exchange rates	Var. at constant exchange rates
Turnover	508.7	414.5	+23%	+21%	177.4	163.0	+9%	+6%
Energy Sales	301.7	237.3	+27%	+24%	111.5	85.2	+31%	+26%
Renvolt	177.8	153.3	+16%	+16%	53.9	68.0	-21%	-21%
Voltalia Hub	29.2	23.9	+22%	+21%	12.1	9.8	+23%	+22%

Turnover for the first nine months of 2026 amounts to 508.7 million euros, up +21% at constant exchange rates (+23% at current exchange rates). It breaks down as 61% in Europe, 32% in Latin America and 7% in the rest of the world, illustrating the continued geographical rebalancing of activities. Energy Sales accounts for 59%, Renvolt for 35% and Voltalia Hub for 6% of turnover for the first nine months of 2026.

Turnover for the third quarter of 2026 amounts to 177.4 million euros, up +6% at constant exchange rates (+9% at current exchange rates). Strong growth in Energy Sales and Voltalia Hub offsets the one-off decline in Renvolt, whose revenues reflect the achievement of construction milestones.

REVIEW OF ACTIVITIES

Energy Sales

Operational indicators	9M 2026	9M 2025	Var.	Q3 2026	Q3 2025	Var.
Production (in GWh)	4,066	3,648	+11%	1,659	1,283	+29%
Production curtailment (in GWh)	443	651	-32%	225	383	-41%
Capacity in operation (in MW)2	3,001	2,554	+18%
Capacity in operation and under construction (in MW)	3,564	3,286	+8%
Wind load factor in Brazil	32%	34%	-2pts	44%	37%	+7pts
Wind load factor in Brazil without curtailment	38%	43%	-5pts	52%	53%	-1pt
Solar load factor in Brazil3	19%	19%	stable	20%	16%	+4pts
Solar load factor in Brazil without curtailment	24%	24%	stable	26%	25%	+1pt
Wind load factor in France	20%	21%	-1pt	15%	17%	-2pts
Solar load factor in France	15%	11%	+4pts	20%	13%	+7pts
Solar load factor in Jordan and Egypt	27%	28%	-1pt	30%	31%	-1pt
Solar load factor in Albania	24%	24%	stable	29%	29%	stable
Solar load factor in the United Kingdom	17%	19%	-2pts	17%	20%	-3pts
Solar load factor in Portugal	22%	22%	stable	26%	27%	-1pt

Production for the first nine months of 2026 amounts to 4.1 TWh, up +11% compared with the first nine months of 2025. This increase reflects growth in capacity in operation and the ramp-up of recently commissioned power plants. Solar and wind account for 55% and 43% of production over the period respectively. It should be noted that battery storage is set to account for a gradually larger share of this energy mix (standalone storage projects and hybrid projects).

Production for the third quarter of 2026 reaches 1.7 TWh, up +29% compared with the third quarter of 2025. This strong increase benefits from the contribution of new power plants, the sharp reduction in curtailment and improved solar and wind resources.

Analysis of quarterly production by region

• In Latin America, production grows by +22%, driven by improved solar and wind resources and the continued decrease in curtailment. Curtailment stands at 225 GWh in the third quarter of 2026, down 41%, confirming the improvement observed since the beginning of the year
• In Europe, production grows by +10%, driven in particular by recently commissioned power plants, notably in French Guiana
• In Africa and internationally, production is multiplied by 3.6, driven by new capacity commissioned
• Helexia production grows by +7%

In million euros	9M 2026	9M 2025	Var. at current exchange rates	Var. at constant exchange rates	Q3 2026	Q3 2025	Var. at current exchange rates	Var. at constant exchange rates
Energy Sales turnover	301.7	237.3	+27%	+24%	111.5	85.2	+31%	+26%
Latin America	141.2	105.8	+34%	+26%	48.3	38.2	+27%	+18%
Europe	73.1	62.3	+17%	+18%	27.7	22.2	+25%	+24%
Africa and international	32.8	22.1	+49%	+49%	13.5	7.7	+74%	+69%
Helexia	54.5	47.2	+16%	+14%	22.0	17.1	+29%	+26%

Turnover from Energy Sales for the first nine months of 2026 reaches 301.7 million euros, up +24% at constant exchange rates (+27% at current exchange rates). This change reflects the contribution of capacity growth (+18%), a favourable currency effect linked to the Brazilian real and the recognition, in the first half, of compensation related to curtailment in Brazil. These drivers offset lower availability at certain wind power plants, which is in the process of being resolved.

Turnover from Energy Sales for the third quarter of 2026 reaches 111.5 million euros, up +26% at constant exchange rates (+31% at current exchange rates), driven by turnover growth across all regions and at Helexia.

Renvolt

In million euros	9M 2026	9M 2025	Var. at current exchange rates	Var. at constant exchange rates	Q3 2026	Q3 2025	Var. at current exchange rates	Var. at constant exchange rates
Turnover	177.8	153.3	+16%	+16%	53.9	68.0	-21%	-21%

Turnover from Renvolt for the first nine months of 2026 amounts to 177.8 million euros, up +16% at constant and current exchange rates, benefiting from the growth recorded in the first half. This increase is driven by momentum in construction activities for third-party clients in Europe (around 600 MW under construction in Ireland and Spain) and in maintenance for third-party clients, notably in Portugal.

Turnover from Renvolt for the third quarter of 2026 amounts to 53.9 million euros, down -21% at constant and current exchange rates. This change mainly reflects the recognition of revenues according to the progress of construction milestones. It does not call into question the growth momentum observed over the first nine months of the year.

Voltalia Hub

In million euros	9M 2026	9M 2025	Var. at current exchange rates	Var. at constant exchange rates	Q3 2026	Q3 2025	Var. at current exchange rates	Var. at constant exchange rates
Turnover	29.2	23.9	+22%	+21%	12.1	9.8	+23%	+22%

Turnover from Voltalia Hub for the first nine months of 2026 amounts to 29.2 million euros, up +21% at constant exchange rates (+22% at current exchange rates). This increase notably reflects growth in specialised activities, including Yusco⁴ and maintenance for third-party clients in Brazil.

Turnover from Voltalia Hub for the third quarter of 2026 amounts to 12.1 million euros, up +22% at constant exchange rates (+23% at current exchange rates), supported by growth across all specialised activities.

NEW ANNOUNCEMENTS

Capacity in operation: 2026 objective reached as early as September⁵

As early as September, Voltalia reaches its objective of 3 GW of capacity in operation, one quarter ahead of schedule, notably thanks to 38 MW of new Helexia capacity commissioned during the third quarter in Europe and Brazil.

Voltalia strengthens its Board of Directors⁶

Following the General Meeting of 9 October 2026, Voltalia strengthens its Board of Directors with the ratification of the co-optation of Isabelle Kocher de Leyritz and the appointment of Emmanuelle Lemer as independent director.

• Isabelle Kocher de Leyritz, co-opted in May 2026 to replace Laurence Mulliez, Chair of Blunomy, brings first-rate experience in strategy, energy transition, governance, finance and corporate transformation, gained notably at Suez and ENGIE, where she was Chief Executive Officer from 2016 to 2020
• Emmanuelle Lemer, also appointed Chair of the Audit Committee, has more than twenty years of experience in energy, infrastructure and investment banking, notably at J.P. Morgan. She brings to the Board recognised expertise in financial markets, strategic transactions and financing.

These appointments strengthen the diversity and complementarity of the Board of Directors’ skills to support Voltalia in the execution of its strategy and its SPRING transformation plan.

OPERATIONAL AND FINANCIAL OBJECTIVES⁷

2026 operational and financial objectives

• Operational objectives reached as early as September 2026: capacity in operation and under construction of around 3.6 gigawatts, including around 3 gigawatts in operation
• Financial objectives: 2026 EBITDA of between 210 and 230 million euros confirmed, including 190 to 210 million euros generated by the Energy Sales business

NEXT ON THE AGENDA:

• 2026 annual results, on 4March 2027 (before market open)

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. These statements do not constitute historical facts. They include projections and estimates and the assumptions on which they are based, statements relating to projects, objectives, intentions and expectations regarding financial results, future events, operations, services, product development and their potential, or future performance. Such forward-looking statements can often be identified by the use of words such as “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan”, as well as other similar terms. Although Voltalia’s management believes that these forward-looking statements are reasonable, investors are cautioned that they are subject to numerous risks and uncertainties that are difficult to predict and generally beyond Voltalia’s control, and that may cause actual results and events to differ materially from those expressed, implied or projected in such forward-looking information and statements. These risks and uncertainties include, in particular, uncertainties inherent in changes in the selling price of the electricity produced by Voltalia, changes in the regulatory environment in which Voltalia operates, and the competitiveness of renewable energy, as well as other factors that may affect the production capacity or profitability of Voltalia’s production sites, and those developed or identified in Voltalia’s public filings with the Autorité des marchés financiers, including those listed in Section 2.2 “Risk factors” of Voltalia’s 2025 Universal Registration Document filed with the Autorité des marchés financiers on 30 March 2026. Voltalia undertakes no obligation to update these forward-looking information and statements, subject to applicable regulations.

Capacity in operation as of September 30, 2026

In MW	Solar	Wind	Biomass	Hydro	Hybrid	Sept. 30, 2026	Sept. 30, 2025
Helexia	603					603	523
Belgium	32					32	23
Brazil	218					218	188
France	217					217	193
Hungary	25					25	25
Italy	25					25	21
Poland	5					5	0
Portugal	27					27	27
Romania	14					14	14
Spain	40					40	32
Voltalia	1,441	854	17	17	68	2,398	2,031
South Africa	148					148	0
Albania	140					140	140
Brazil	584	773		8	12	1,377	1,369
Egypt	32					32	32
France	93	81		5		179	160
Greece	31					31	20
French Guiana	13		17	5	24	59	48
Italy	3					3	3
Jordan	57					57	57
Uzbekistan	126					126	0
Netherlands	60					60	60
Portugal	52					52	52
United Kingdom	102				32	134	89
Total	2,044	854	17	17	68	3,001	2,554

Capacity under construction as of September 30, 2026

Project name	Capacity (MW)	Technology	Country
Helexia	57
Helexia	37	Solar	Brazil
Helexia	11	Solar	France
Helexia	3	Solar	Italy
Helexia	3	Solar	Poland
Helexia	1	Solar	Portugal
Helexia	1	Solar	Spain
Voltalia	506
Artemisya storage	100	Storage	Uzbekistan
Artemisya wind	100	Wind	Uzbekistan
East gate	34	Solar	United Kingdom
Higher Stockbridge	45	Solar	United Kingdom
Los Venados	20	Solar	Colombia
Saint Anne hybrid	7	Hybrid	French Guiana
Saint Anne solar	43	Solar	French Guiana
Saint Anne storage	34	Storage	French Guiana
Spitalla solar	100	Solar	Albania
Voltalia Mobility – Yusco	24	Solar	France
Total	563

Electricity production as of September 30, 2026

In GWh	Wind	Solar	Biomass	Hydro	Hybrid	Sept. 30, 2026	Sept. 30, 2025
Helexia		505				505	457
Helexia Brazil		224				224	178
Helexia Europe		282				282	279
Voltalia	1,759	1,718	31	5	47	3,561	3,191
South Africa		137				137	0
Albania		223				223	223
Brazil	1,662	739			46	2,446	2,448
Egypt		58				58	59
France	98	73		5		176	177
Greece		30				30	22
French Guiana		11	31		1	43	21
Italy		3				3	4
Jordan		103				103	105
Uzbekistan		207				207	0
Portugal		73				73	74
United Kingdom		62				62	57
Total	1,759	2,223	31	5	47	4,066	3,648

Quarterly electricity production (Q3) 2026

In GWh	Wind	Solar	Biomass	Hydro	Hybrid	Q3 2026	Q3 2025
Helexia		183				183	170
Helexia Brazil		81				81	59
Helexia Europe		102				102	111
Voltalia	775	666	14	4	17	1,476	1,113
South Africa		66				66	0
Albania		91				91	91
Brazil	751	256			17	1,024	837
Egypt		21				21	20
France	24	35		4		63	59
Greece		14				14	10
French Guiana		4	14			19	5
Italy		0				0	2
Jordan		40				40	40
Uzbekistan		86				86	0
Portugal		29				29	30
United Kingdom		23				23	20
Total	775	849	14	4	17	1,659	1,283

Average EUR/BRL rate

Average rate	9M 2026	9M 2025
EUR/BRL	5.98	6.32

Main expected impacts of the SPRING transformation plan between 2026 and 2030

KEY INDICATORS	FINANCIAL IMPACT	OUTLOOK
EBITDA objective	300-325 million euros	2027
Energy Sales EBITDA	270-300 million euros	2027
EBITDA margin
Energy Sales	70%-72%	2030
Services	9%-11%	2030
Cash flow & impact on capital
Disposals	300-350 million euros	Between 2026 and 2028
Long-term financial stability
Net debt/EBITDA ratio	Between 7.5 and 8	2030

About Voltalia (www.voltalia.com)
Voltalia is an international player in renewable energy. The Group produces and sells electricity from its wind, solar, hydro, biomass and storage facilities. It has 3.6 GW of capacity in operation and under construction, and a portfolio of projects under development with a total capacity of 12 GW. Voltalia is also a service provider, supporting its renewable energy customers at every stage of their projects, from design to operation and maintenance. A pioneer in the business market, Voltalia offers a comprehensive range of services to businesses, from the supply of green electricity to energy efficiency services and the local production of its own electricity. With 1,900 employees in 15 countries on 3 continents, Voltalia has the capacity to act globally on behalf of its customers. Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 – VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included, amongst others, in the MSCI ESG ratings and the Sustainalytics ratings.
Voltalia Email: invest@voltalia.com T. +33 (0)1 81 70 37 00	Press relations – SEITOSEI.ACTIFIN – Jennifer JULLIA  jennifer.jullia@seitosei-actifin.com  T. +33 (0)6 02 08 45 49

---

[1] See appendix for details of the expected impacts of SPRING
² Capacity as of September 30, 2026 vs capacity as of September 30, 2025.
³ The calculation of load factors was reviewed and updated during the period in order to better reflect the actual performance of the portfolio in operation. Load factors are now weighted by the installed capacity of each power plant and by the number of hours during which it was available over the period, which notably makes it possible to take into account commissionings and changes in scope during the year. The 2025 load factors presented for comparison have been restated in line with this new methodology. By way of illustration, before restatement, the solar load factor in Brazil for the first nine months of 2025 was 23%.
⁴ Electric vehicle charging operator.
⁵ Today’s announcement.
⁶ Press release dated 13 October 2026.
⁷ Section: Operational and Financial Objectives, from the press release on the 2026 half-year results, September 3, 2026.

Attachment

• Turnover of 177 million euros in the third quarter

Paris, October 22, 2026

Press release

UNIBAIL-RODAMCO-WESTFIELD Q3-2026 TRADING UPDATE

CONTINUED OPERATING MOMENTUM SUPPORTS 2026 OUTLOOK

• Solid operating performance in 9M-2026
  • Tenant sales up +5.2% and footfall up +2.2%
  • Rental uplift of +10.3% on top of indexed passing rents, vs. +6.7% in 2025
  • EPRA Shopping Centres vacancy at 3.9%, improved by 140 bps vs. 9M-2025 and 20 bps vs. H1-2026
• Like-for-like turnover up +2.4% incl. like-for-like Shopping Centres GRI up +3.8%
• Signing of a consulting agreement with Thailand’s Asset World Corporation, covering three flagship developments in Thailand representing a first step towards a future potential franchising partnership
• Further capital recycling with the agreement to acquire the remaining 50% stake in Metropole Zličín funded by non-core disposals secured in Q3-2026 beyond the €2.2 Bn disposal plan
• €520 Mn of successful financings at attractive spreads, with the Group’s macro-hedging policy protecting earnings from sharp increases in interest rates and maintaining the average cost of debt in line with ‘A Platform for Growth’ 2025-28 guidance
• Moody’s upgraded URW’s credit rating to Baa1 with a stable outlook
• 2026 Adjusted Recurring Earnings per Share (AREPS) expected to be within its guidance of €9.15 to €9.30.
• ‘Unpacking Data & AI: the Westfield approach’ organised in London at Westfield Stratford City on December 3, 2026, showcasing how data and AI enhance URW’s operating model and drive performance

Commenting on the results, Vincent ROUGET, Chief Executive Officer, said:

“Our solid Q3 results are underpinned by strong growth in tenant sales and footfall, robust leasing activity and continued reduction in vacancy to record-low levels. Positive momentum in rental uplifts was sustained during the quarter, and we are on track to achieve our FY-2026 AREPS guidance and pay a cash distribution of €5.50 per share.

During the quarter, we expanded the Westfield network through flagship rebrandings in Poland and the UK and successfully refinanced €0.5 billion at attractive spreads. Moody’s recent upgrade of the Group to Baa1 further recognises our operating and financial strength.

We are also advancing our use of data and AI to make better decisions, improve operational efficiency and drive performance for our retail partners and for URW. We look forward to sharing our progress in this area with investors and analysts in December.

With strong operating momentum, our diversified global platform and a clear focus on executing our ‘A Platform for Growth’ business plan, we have confidence in the Group’s financial trajectory despite the volatile geopolitical and macroeconomic environment.”

For more information, please contact:

Investor Relations
Meriem Delfi – +33 7 63 45 59 77 – investor.relations@urw.com
Juliette Aulagnon – +33 6 15 74 20 43 – investor.relations@urw.com

Media Relations 
UK/Global: Ariane Laval – FinElk   – +44 7570 727 531 – Ariane.Laval@finelk.eu 

France:
Franck Pasquier – Image 7 – +33 6 73 62 57 99 – fpasquier@image7.fr
Nathalie Feld – Image 7 – +33 6 30 47 18 37– nfeld@image7.fr

About Unibail-Rodamco-Westfield

Unibail-Rodamco-Westfield (URW) operates vibrant retail-anchored destinations in many of the world’s best cities and urban areas. This powerful network attracts over 900 million customer visits annually, supports the growth of major retailers, and makes a significant social and economic contribution to local communities.

This network includes 65 owned shopping centres in the US and Europe that represent around 88% of the Group’s €49.5 Bn asset portfolio – with 41 centres operating under the iconic Westfield brand. URW also has partners who operate Westfield-branded destinations in fast-growing new markets.

Through its ‘A Platform for Growth’ business plan, URW is generating organic growth, leveraging the power of the Westfield brand, and unlocking capital light growth opportunities to generate compelling shareholder returns. This is supported by the Group’s ‘Better Places’ sustainability roadmap, which has established URW as a leader in the real estate industry and one of the 100 most sustainable companies in the world.

URW’s shares are listed on Euronext Paris (Ticker: URW). The Group is rated BBB+ by Standard & Poor’s and Baa1 by Moody’s.

For more information, please visit www.urw.com

Attachment

• UNIBAIL-RODAMCO-WESTFIELD Q3-2026 TRADING UPDATE

PARIS

October 22, 2026

Third quarter in line with annual objectives Valeo confirms its FY 2026 guidance

Q3 sales at 4.9 billion euros, down 2.6% on a like-for-like basis

North America and Asia (excluding China) continued to outperform; original equipment sales of 4.1 billion euros, down by 3.8% like for like in a market that was down 1.6% overall

BRAIN Division returned to growth with sales up 8.2% on a like-for-like basis, marking the first step towards the Group’s return to growth in 2027

FY 2026 objectives confirmed:

● Sales: 20 to 21 billion euros

● Operating margin (as a % of sales): 4.7% to 5.3%

● Free cash flow (after net financial interest) of more than 400 million euros

● Valeo is targeting second-half operating margin (as a % of sales) and free cash flow equivalent to those of the first half

“Our performance in the third quarter is in line with our objectives for the full year, demonstrating Valeo’s resilience in a demanding market environment where challenges have intensified over recent months.

In this context, the rebound in activity in the BRAIN Division provides a positive signal. It sets the first concrete milestone toward the Group’s return to growth in 2027, the third engine of our “Elevate 2028” strategic plan.

We are entering the final quarter with the same absolute rigor in operational execution and cost management. Our teams are fully mobilized to tackle the headwinds and deliver on all our objectives for the full year.” 

 Christophe Périllat, Valeo’s Chief Executive Officer

Sales of 4,881 million euros in the third quarter of 2026, down 2.6% like for like

SALES

(in millions of euros)	As a % of sales	Q3 2026	Q3 2025	Change	FX	Scope	LFL* change
Original equipment	84%	4,080	4,229	-3.5%	+1.1%	-0.8%	-3.8%
Aftermarket	10%	516	503	+2.6%	-0.2%	-0.1%	+3.0%
Miscellaneous	6%	285	265	+7.6%	+1.1%	0.0%	+6.6%
TOTAL	100%	4,881	4,997	-2.3%	+1.0%	-0.7%	-2.6%
* On a like-for-like basis1.

Based on S&P Global Mobility estimates, automotive production was down 1.6% year on year in the third quarter of 2026.

Total sales for third-quarter 2026 came in at 4,881 million euros, down 2.3% compared with the same period in 2025.

Changes in Group structure had a negative 0.7% impact linked to the disposal of the automotive powertrain systems sensor business in November 2025 (POWER Division).

Exchange rates had a positive impact of 1.0%, due to the increase in value of international currencies against the euro, particularly the US dollar and Chinese renminbi.

On a like-for-like basis, sales were down 2.6%.

Original equipment sales contracted by 3.8% like for like, representing a gap in performance versus global automotive production of 2.2 percentage points, taking into account a positive 0.8 percentage point geographic mix effect. These sales were affected by an unfavorable base effect related to customer compensation recorded in the POWER Division in the third quarter of 2025. 

Aftermarket sales rose by 3.0% on a like-for-like basis compared with the prior-year period, supported by ongoing momentum in North America, Asia and Europe.

“Miscellaneous” sales, essentially comprising customer contributions to R&D costs and prototypes, were up 6.6% on a like-for-like basis.

North America and Asia (excluding China) continue to outperform

ORIGINAL EQUIPMENT SALES***

(in millions of euros)	As a % of sales	Q3 2026	Q3 2025	Change	LFL* change	Perf.**
Europe	46%	1,891	2,058	-8.1%	-7.1%	-7 pts
Asia (excluding China)	18%	717	681	+5.3%	+7.5%	+3 pts
China	13%	534	576	-7.3%	-12.9%	-7 pts
North America	21%	840	826	+1.7%	0.0%	+5 pts
South America	2%	98	88	+11.6%	+5.2%	-1 pt
TOTAL	100%	4,080	4,229	-3.5%	-3.8%	-2 PTS
* On a like-for-like basis. ** Based on S&P Global Mobility automotive production estimates released on October 15, 2026 (Q3 2026 estimated global production: -1.6%). *** Original equipment sales by destination region. Europe includes Africa. Asia (excluding China) includes the Middle East and Oceania.

Third-quarter original equipment sales saw a gap in performance of 2.2 percentage points versus automotive production, while also benefiting from a favorable geographic mix effect of 0.8 percentage points.

In Europe, the 7-percentage point gap in performance versus automotive production reflects a downturn in the POWER Division, largely attributable to an unfavorable base effect, offset by the continued strong performance of the LIGHT and BRAIN Divisions.

In Asia (excluding China), which was buoyed by strong performance from the POWER and LIGHT Divisions, Valeo posted growth of 7.5% on a like-for-like basis, an outperformance of 3 percentage points compared with automotive production.

In China, in a declining and particularly volatile market, Valeo posted a gap in performance versus automotive production of 7 percentage points. While business volumes with local automakers were down slightly, efforts to reposition the customer portfolio continue to advance (56% of original equipment sales to Chinese automakers since the start of the year, compared with 52% in 2025 over the same period and 53% in first-half 2026).

 In North America, Valeo posted a 5-percentage point outperformance with sales remaining stable on a like-for-like basis, driven by the ongoing momentum of the POWER Division.

Segment reporting

Growth resumption in the BRAIN Division in third-quarter 2026

SALES BY DIVISION

(in millions of euros)	Q3 2026	Q3 2025	Change in sales	Change in OE sales*	Perf.**
POWER	2,396	2,599	-7.8%	-9.6%	-8 pts
BRAIN	1,198	1,106	+8.3%	+8.2%	+10 pts
LIGHT	1,267	1,282	-1.2%	-3.2%	-2 pts
OTHER	20	10	ns	ns	ns
GROUP	4,881	4,997	-2.3%	-3.8%	-2 PTS
* On a like-for-like basis. ** Based on S&P Global Mobility automotive production estimates released on October 15, 2026 (Q3 2026 estimated global production: -1.6%).

In the third quarter, the POWER Division posted a 8‑percentage point gap in performance, caused by unfavorable base and mix effects in Europe. Growth remains robust, however, in North America and Asia, particularly for electrification technologies in India.

With an 8.2% increase on a like-for-like basis, the BRAIN Division returned to growth in the third quarter and outperformed the market by 10 percentage points. This performance reflects continued strong momentum in the display and telematics activities, as well as the ramp-up in production of vision systems for a major European automaker.

The LIGHT Division saw a gap in performance versus automotive production of 2 percentage points. Momentum remains strong in Europe and Asia (excluding China), driven by lighting programs for premium and volume vehicles. Following success with Chinese automakers and a peak in production launches in the second half of 2025, business in China has returned to normal levels. 

2026 guidance confirmed

Third-quarter sales are in line with annual objectives. For the fourth quarter, Valeo anticipates sequential growth in line with typical seasonality.

The Group confirms its 2026 guidance (as set out in the table below), and is targeting an operating margin (as a % of sales) and free cash flow in the second half of the year equivalent to those of the first half.

	2025	2026 guidance*
Sales (in billions of euros)	20.9	20-21
Operating margin (as a % of sales)	4.7%	4.7%-5.3%
Free cash flow after net financial expenses (in millions of euros)	371	>400
* Based on S&P Global Mobility estimates at October 15, 2026. The forecasts assume that there will be no additional material changes to tariffs or trade restrictions in force on October 22, 2026, nor any significant changes in market conditions, macroeconomic projections or major supply chain disruptions.

Upcoming events

2026 annual results:  February 25, 2027

First-quarter 2027 results: April 28, 2027

Financial glossary

Order intake corresponds to business awarded by automakers during the period to Valeo, and to joint ventures and associates based on Valeo’s share in net equity, less any cancellations, based on Valeo’s best reasonable estimates in terms of volumes, selling prices and project lifespans.   Unaudited indicator.

Like for like (or LFL): the currency impact is calculated by multiplying sales for the current period by the exchange rate for the previous period. The Group structure impact is calculated by (i) eliminating, for the current period, sales of companies acquired during the period, (ii) adding to the previous period full-year sales of companies acquired in the previous period, and (iii) eliminating, for the current period and for the comparable period, sales of companies sold during the current or comparable period.

Operating margin corresponds to operating income before other income and expenses and before share in net earnings of equity-accounted companies.

Free cash flow (new definition) corresponds to net cash from operating activities (excluding changes in non-recurring sales of receivables) after taking into account (i) acquisitions and disposals of property, plant and equipment and intangible assets, (ii) payments for the principal portion of lease liabilities and (iii) net financial interest.

APPENDICES

Sales

Sales (in millions of euros)	As a % of sales	YTD 2026	YTD 2025	Change	LFL* change	FX	Scope
Original equipment	83%	12,624	13,133	-3.9%	-1.6%	-1.5%	-0.8%
Aftermarket	10%	1,618	1,617	+0.1%	+2.4%	-2.2%	-0.1%
Miscellaneous	7%	1,016	907	+12.1%	+13.2%	-1.1%	0.0%
TOTAL	100%	15,259	15,657	-2.5%	-0.3%	-1.5%	-0.7%
* On a like-for-like basis.

Sales by destination region***

Original equipment sales (in millions of euros)	As a % of sales	YTD 2026	YTD 2025	LFL* change	Perf. **
Europe	49%	6,229	6,580	-4.5%	-6 pts
Asia (excluding China)	17%	2,077	2,094	+6.6%	+3 pts
China	12%	1,539	1,704	-10.2%	-5 pts
North America	20%	2,515	2,519	+4.1%	+6 pts
South America	2%	264	237	+6.9%	+1 pt
TOTAL	100%	12,624	13,133	-1.6%	-1 PT
* On a like-for-like basis. ** Based on S&P Global Mobility automotive production estimates released on October 15, 2026. *** Original equipment sales by destination region. Europe includes Africa. Asia (excluding China) includes the Middle East and Oceania

Sales by Division

Sales by Divisions (in millions of euros)	YTD 2026	YTD 2025	Change in sales	Change in OE sales*	Perf. **
POWER	7,514	8,002	-6.1%	-4.0%	-3 pts
BRAIN	3,731	3,632	+2.7%	+2.2%	+3 pts
LIGHT	3,987	4,010	-0.6%	-0.6%	0 pts
OTHER	27	13	ns	ns	ns
GROUP	15,259	15,657	-2.5%	-1.6%	-1 PT
* On a like-for-like basis. ** Based on S&P Global Mobility automotive production estimates released on October 15, 2026.

Safe Harbor Statement

Statements contained in this document which, when they are not historical fact, constitute “forward-looking statements”. These statements include projections and estimates and their underlying assumptions, statements regarding projects, objectives, intentions and expectations with respect to future financial results, events, operations, services, and product development and potential and future performance. Even though Valeo’s Management feels that the forward-looking statements are reasonable as at the date of this document, investors are put on notice that the forward-looking statements are subject to numerous factors, risks and uncertainties that are difficult to predict and generally beyond Valeo’s control, which could cause actual results and events to differ materially from those expressed or projected in the forward-looking statements. Such factors include, among others, the Company’s ability to generate cost savings or manufacturing efficiencies to offset negotiated or imposed price reductions. The risks and uncertainties to which Valeo is exposed mainly comprise the risks related to the automotive equipment industry and to the development and launch of new products and risks due to certain global and regional economic and geopolitical conditions, environmental and industrial risks as well as risks and uncertainties described or identified in the public documents submitted by Valeo to the French financial markets authority (Autorité des marchés financiers – AMF), including those set out in the “Risk Factors” section of the 2025 Universal Registration Document registered with the AMF on March 31, 2026 (under number D.26–0184).

In addition, other risks which are currently unidentified or considered to be non-material by the Group, could have the same adverse impact and investors could lose all or part of their investment. Forward-looking statements are given only as at the date of this document and Valeo does not undertake to update the forward-looking statements to reflect events or circumstances which occur subsequent to the publication of this document. Valeo assumes no responsibility for any analyses issued by analysts and any other information prepared by third parties which may be used in this document. Valeo neither intends to review, nor will it confirm, any estimates issued by analysts.

About Valeo

Valeo is a global technology leader, designing innovative solutions and systems for its automotive and technology partners. The Group is organized around its POWER, BRAIN and LIGHT Divisions, and Valeo Service, which offers solutions for after-sales and new forms of mobility.

Valeo is committed to making mobility safer, more sustainable and more affordable for everyone. The Group is at the heart of tomorrow’s cars: electrified, safer and software-driven. It enjoys technological and industrial leadership in the key areas that are transforming mobility – electrification, ADAS, software-defined vehicles and interior experience reinvention. 

Valeo is listed on the Paris Stock Exchange. 

Valeo at a glance: 20.9 billion euros in sales in 2025 | 100,000 employees worldwide | 29 countries | 149 plants | 59 R&D centers | 19 distribution platforms (at February 26, 2026).

Learn more at www.valeo.com 

Find all our press releases: https://www.valeo.com/en/press-releases/

Media Relations

Dora Khosrof | +33 7 61 52 82 75

Caroline De Gezelle | +33 7 62 44 17 85

press-contact.mailbox@valeo.com

Investor Relations

Marisa Baldo | marisa.baldo@valeo.com

valeo.corporateaccess.mailbox@valeo.com

---

¹ See financial glossary, page 4.

Attachment

• PR Q3 2026 Sales

New late-breaking data presented today at ASN Kidney Week 2026

QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort

No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today new positive data from the late-breaking presentation at ASN Kidney Week 2026 in Denver, Colorado.

The late-breaking poster, titled “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort,” compared survival in QUELIMMUNE (SCD-PED)-treated critically ill pediatric patients from its post-approval SAVE registry and one non-registry patient with life-threatening acute kidney injury (AKI) and sepsis requiring CRRT (QUELIMMUNE SCD-PED cohort) with clinically aligned cohorts from Kids’ Inpatient Database (KID), the largest publicly available, all-payer pediatric inpatient care database in the United States representing broad clinical complexity. To assess the robustness of the findings, the authors used a multi-pronged analytic approach that included both Bayesian and frequentist methods across primary, landmark, and time-to-event analyses. Key results are reported. A separate safety analysis of QUELIMMUNE (SCD-PED)-treated patients was also presented.

Summary of Key Highlights:

• Day 90 Survival:   The primary exposure-defined analysis at Day 90 resulted in a statistically significant increase in survival of the QUELIMMUNE (SCD-PED) cohort achieving 65.1% survival compared to 47.4% for the KID cohort (P = 0.043), representing more than double the odds of survival for QUELIMMUNE (SCD-PED)-treated patients (odds ratio [OR] 2.07; 95% confidence interval, [CI] 1.04-4.11). The Bayesian probability of higher survival in QUELIMMUNE (SCD-PED) patients was 98.2%. A second landmark sensitivity analysis favored the QUELIMMUNE (SCD-PED) cohort achieving 63.8% Day 90 survival, an increase of 15.1 percentage points over the KID cohort survival of 48.7% (P= 0.074), representing 86% higher estimated odds of survival (OR 1.86; 95% CI, 0.96-3.60). The Bayesian probability of higher survival in the QUELIMMUNE (SCD-PED) landmark cohort was 96.8%.
• In-Hospital Survival: Survival to hospital discharge was significantly higher with the QUELIMMUNE (SCD-PED) cohort compared to KID in the primary analysis (P = 0.04). Bayesian analyses were directionally consistent, with 98.5% and 97.3% posterior probabilities of higher QUELIMMUNE (SCD-PED) survival in the primary and landmark analyses, respectively.
• Mortality: All four Day 90 mortality models favored the QUELIMMUNE (SCD-PED) cohort showing 34% to 40% reduction in estimated hazard of mortality (Hazard Ratio range, 0.60-0.66) compared with combined KID. While frequentist models did not reach statistical significance, both Bayesian time-to-death models exceeded the 95% probability threshold, providing supportive evidence of a lower mortality hazard with QUELIMMUNE therapy.
• Renal Replacement Therapy (RRT) Independence: 20 of the 24 survivors (83%) in the QUELIMMUNE (SCD-PED) cohort who did not require RRT at baseline were independent of RRT at 90 days.
• Adverse Events (AEs): No device-related AEs occurred in patients treated with the QUELIMMUNE (SCD-PED) therapy from SAVE registry patients. All new bloodstream infections (12% overall and 6% during treatment) within 28 days of SCD-PED initiation were adjudicated by an independent data and safety monitoring board to be unrelated to QUELIMMUNE therapy.

“These real-world, post-approval data show a significant association with higher survival and a consistent safety profile in the QUELIMMUNE (SCD-PED)-treated patients with sepsis-associated AKI requiring CRRT with a broad range of clinical complexities,” said Stuart Goldstein, MD, Director, Center for Acute Care Nephrology at Cincinnati Children’s and a member of the SeaStar Medical Scientific Advisory Board.* “The consistency of the survival signal across analyses support continued and further exploration of these and additional data that is forthcoming from new patients. Given the urgency of this rare and life-threatening condition combined with no device-related adverse events, I believe there is a clear observed potential benefit from the SCD-PED therapy with a favorable safety profile.”

“Selection as a late-breaker at ASN Kidney Week reflects the urgent need for better options for critically ill children with sepsis-associated AKI,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “These real-world findings are consistent with our previous clinical results and the association with higher survival held across every analytic approach we applied. Sharing them with the nephrology community at its premier meeting is an important step toward making QUELIMMUNE therapy available to every child who may benefit.”

Statistical Design and Analyses:

The observational external-control exploratory study compared all known eligible QUELIMMUNE (SCD-PED)-treated pediatric patients (SAVE Registry patients plus one non-registry patient) with available outcome data through completion of the pre-specified SAVE enrollment target of 50 patients versus clinically aligned patients from the 2019 and 2022 Healthcare Cost and Utilization Project Kids’ Inpatient Databases (KID). KID is the largest publicly available all-payer pediatric inpatient care database in the United States, containing unweighted data from over three million pediatric discharges per data year, representing a broad range of patients, comorbidities, and complexities, including extracorporeal membrane oxygenation (ECMO), thus provided the broadest available pediatric comparator population. Both cohorts included critically ill pediatric patients with life-threatening AKI and sepsis requiring CRRT with high clinical complexities, such as malignancy, immunocompromised status and transplant. Greater than 95% required invasive mechanical ventilation, vasopressor use, and/or management for shock in both groups. Advanced life support therapy, such as ECMO, was administered in 33% to 34% of patients in the SAVE cohort and 28% to 29% of patients in the KID cohort.

The primary exposure-defined analysis compared the QUELIMMUNE (SCD-PED) cohort patients who received greater than one day of QUELIMMUNE therapy (N=43) versus clinically aligned patients in the KID cohort (N=196).

The landmark sensitivity analysis compared the QUELIMMUNE (SCD-PED) cohort patients who were alive one day post-initiation of QUELIMMUNE therapy (N=47) versus patients from the KID cohort who survived beyond one calendar day of CRRT initiation (N=191).

Safety outcomes for the QUELIMMUNE (SCD-PED) cohort included new bloodstream infections and Day 90 renal replacement therapy (RRT)-free status among survivors not RRT-dependent at baseline.

Data Source: The authors acknowledge the source of the data as the Kids’ Inpatient Database (KID), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, Interpretations and conclusions from these data are those of the authors and do not constitute the findings, policies, or recommendations of the U.S. Government, the U.S. Department of Health and Human Services, or AHRQ.

The poster with all results as of the presentation will be available on the Healthcare Professional section of the SeaStar Medical website. Please note data from the original posted abstract was updated and the poster presentation of data is the official data source. Final study results and interpretations are expected to be reported in a peer-reviewed manuscript.

About QUELIMMUNE

The QUELIMMUNE^® (SCD-PED) therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more and aged ≤22 years who are on antibiotics and being treated in the ICU with RRT. It was approved in February 2024 under a Humanitarian Device Exemption application.

Data from two clinical trials of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge.

In February 2026, data published in the prestigious, peer-reviewed journal, Pediatric Nephrology, highlighted the early experience from the QUELIMMUNE SAVE Registry, a post-approval surveillance registry, evaluating the role of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring renal replacement therapy. The publication reported observations from the first 21 pediatric patients with AKI and sepsis requiring renal replacement therapy. Data showed no device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, preliminary outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These findings are broadly consistent with the survival observations reported in the registration studies reported in Kidney Medicine.

The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and could have broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

QUELIMMUNE was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit.  The effectiveness of this device for this use has not been demonstrated. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia. Additional risks may include blood loss or extracorporeal circuit complications. QUELIMMUNE must be used with citrate anticoagulation.

For complete risk information, please see: https://seastarmedical.com/quelimmune 

About the SeaStar Medical Selective Cytopheretic Device (SCD) Therapy

The SCD therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy is designed for broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future CRRT, including dialysis, and prevent loss of life.  

About NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as severe infections or other septic conditions, severe trauma, surgery, and organ failures. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the potential benefit from the SCD-PED therapy with a favorable observed safety profile; anticipated improved survival in real-world critical care practice; anticipated adoption our products; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

*As a member of the SeaStar Medical Scientific Advisory Board, Dr. Goldstein has received financial compensation for his service in this capacity.

MCLEAN, Va., Oct. 22, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey^® (PMMS^®), showing the 30-year fixed-rate mortgage (FRM) averaged 7.32%.

“The average 30-year fixed-rate mortgage declined this week, offering some relief to prospective homebuyers,” said Sam Khater, Freddie Mac’s Chief Economist.

News Facts

• The 30-year FRM averaged 7.32% as of October 22, 2026, down from last week when it averaged 7.40%. A year ago at this time, the 30-year FRM averaged 6.19%.
• The 15-year FRM averaged 6.68%, down from last week when it averaged 6.71%. A year ago at this time, the 15-year FRM averaged 5.44%.

The PMMS^® is focused on conventional, conforming, fully amortizing home purchase loans for borrowers who put 20% down and have excellent credit. For more information, view our Frequently Asked Questions.

Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | X | LinkedIn | Facebook | Instagram | YouTube

MEDIA CONTACT:
Mollie Laniado
(571) 382-1784
Mollie_Laniado@FreddieMac.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/790fcf36-11b5-4afb-ab26-99ebf2be22ec 

• Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection
• Structural modeling provides new insight into izicopan’s differentiated molecular profile

Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 – 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases.

“The pre-clinical data presented at Kidney Week demonstrate the ability of izicopan to attenuate renal injury and provide a strong rationale for further development in renal diseases. Combined with its differentiated pharmacokinetic profile, including potentially reduced drug–drug interaction liability, faster onset of action, and more convenient dosing, we believe these results further support izicopan’s best-in-class potential,” said Renfeng Guo, MD, Chief Scientific Officer and Founder of InflaRx. “There is an important need for effective, safer treatment options for patients with complement-mediated inflammatory diseases, particularly in renal indications. We are excited to be advancing oral izicopan in ANCA-associated vasculitis as well as in additional kidney diseases.”

Izicopan was evaluated in two established hamster models of kidney injury: renal ischemia–reperfusion injury (IRI), a model of acute kidney injury, and unilateral ureteral obstruction (UUO)-induced nephropathy, a model of progressive renal injury and fibrosis. In both settings, oral izicopan significantly attenuated renal injury compared to vehicle-treated controls.

IRI model: A single oral dose of izicopan (100 mg/kg), administered four hours before surgery, significantly reduced plasma levels of the renal function markers creatinine and blood urea nitrogen (BUN) compared to vehicle (p < 0.001 for both). Izicopan also significantly improved the overall histopathological (H&E) score of the kidney, as well as the infarction and necrotic area scores (p < 0.05 for each).

UUO model: Izicopan, administered orally five hours before surgery and then once daily for 14 days, significantly reduced BUN levels (p < 0.001) and significantly improved the total H&E histopathological score (p < 0.05) compared to vehicle. Izicopan also showed a numerical trend toward reduced kidney fibrosis (p = NS), as assessed by Masson’s trichrome staining, and α-smooth muscle actin (α-SMA)-positive cell counts.

The structural modeling presented provides new insight into the differentiated molecular profile of izicopan. Compared with avacopan, izicopan preserves the key structural features required for high-affinity C5aR1 binding, while its trifluoromethyl substituent reduces interaction with CYP3A4/5, providing a molecular rationale for its low potential for clinically relevant time-dependent inhibition (TDI).

The poster, entitled “Izicopan, a second-generation oral C5a receptor 1 (C5aR1) antagonist, demonstrates promising therapeutic potential in kidney disease models”, can be accessed here.

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. InflaRx is planning for development of izicopan in ANCA-associated vasculitis (AAV) and additional renal indications.

In contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4/5), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7).

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the therapeutic potential of izicopan in renal and other complement-mediated diseases; the success of our future clinical trials for izicopan’s treatment of AAV and other renal diseases, including aHUS, IgAN and C3G, and our ability to establish proof of concept for izicopan across such indications; the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other of our product candidates; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including potential regulatory paths in AAV for vilobelimab and izicopan and related discussions with EMA; the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval and/or marketing authorization for any indication; potential strategic transactions or collaborations, including a potential partnership of izicopan or vilobelimab for PG; whether the FDA, EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes, the optimization of our manufacturing methods and processes, and our ability to rely on existing third-party manufacturers or engage additional third-party manufacturers for planned future clinical trials and commercial supply; our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or authorized, any commercial sales; if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory oversight; our ability to comply with enacted and future legislation in seeking marketing approval, authorization or commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors (including avacopan) and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

NACON UNVEILS THE REVOLUTION PRO X – SE,
A WIRELESS CONTROLLER THAT ADJUSTS JOYSTICK SENSITIVITY

Officially licensed by XBOX, the REVOLUTION PRO X – Special Edition combines joysticks with adjustable tension, Hall Effect technology and highly responsive micro-switches to deliver precise, customizable control on XBOX, PC, and Smart TVs.

Lesquin (France), October 22, 2026 – NACON, a major video game publisher and designer of premium gaming accessories, announces the availability of the REVOLUTION PRO X – SE, its new officially licensed XBOX* wireless precision controller. It is available now across Europe and on the nacongaming.com website.

Watch the announcement trailer of the REVOLUTION PRO X – Special Edition: https://youtu.be/xE3Zj_xrydU

Designed for competitive online gaming (FPS, TPS, racing games, and extraction shooters), the REVOLUTION PRO X – SE allows players on PC, XBOX Series X|S, XBOX One, and Smart TVs to fine-tune their controls to suit their playstyle. Its control ring lets you adjust the mechanical tension of the joysticks with a single gesture to prioritize either fast movements or precise aiming, depending on the situation.

The REVOLUTION PRO X – SE features a minimalist design inspired by Hell is Us art style. It incorporates Hall Effect joysticks, buttons and instant triggers equipped with micro-switch, as well as two programmable shortcut buttons on the back. On PC, it can be used in wired mode with a 1,000 Hz polling rate, corresponding to a claimed latency of 1 ms, to prioritize responsiveness.

“With the REVOLUTION PRO X – SE, we wanted to offer a full-featured precision controller at a competitive price,” says Yannick Allaert, Director of the Accessories Division at NACON. “Its joystick tension adjustment, Hall Effect sensors, and micro-switch combine technologies designed to allow every player to tailor their controls to their playing style.”

The REVOLUTION PRO X – SE is available now across Europe and on the official nacongaming.com website at a RRP of €129.99 / £109.99.

About NACON
NACON is a BIGBEN Group company founded in 2019 to optimize its strong synergies in the video game market. By bringing together its development studios, AA game publishing, and the design and distribution of premium gaming peripherals, NACON focuses 40 years of expertise on serving gamers. This new unified hub strengthens NACON’s position in the market and enables it to innovate by creating unique competitive advantages. https://corporate.nacongaming.com/

*XBOX, XBOX Series X|S are trademarks of the Microsoft group of companies. All Rights Reserved

Attachment

• CP_NACON_Revolution_PRO_X_SE_Diffusion English